Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02263209

Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip Arthroplasty

Prospective clinical investigation to determine the safety of Taperloc stems with BioGuard coating and Exceed ABT Taperfit acetabular cups with BioGuard coating when used in cementless total hip arthroplasty

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

RJAH

Oswestry, United Kingdom

About this study

Bioguard Safety Study: Prospective clinical investigation to determine the safety of Taperloc stems with BioGuard coating and Exceed ABT Taperfit acetabular cups with BioGuard coating when used in cementless total hip arthroplasty

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible for cementless primary total hip arthroplasty according to the Surgical Technique brochure (Appendix 10): "The Taperloc Porous Primary Hip and Exceed ABT Taperfit Prostheses are marketed for non-cemented use in skeletally mature patients undergoing primary hip replacement surgery of non inflammatory degenerative joint disease."
  • Under 80 and over 40 years of age
  • A pre-operative level of pain and function the same as for conventional joint replacement.
  • A likelihood of obtaining relief of pain and improved function
  • Full skeletal maturity
  • Ability to follow instructions
  • Good general health for age
  • Willing to return for follow-up evaluations

Exclusion criteria

  • Patients aged over 80 and under 40 years
  • Known allergy to any antibiotics
  • Active infection
  • Revision arthroplasty
  • Marked bone loss which could preclude or compromise adequate fixation of the device
  • Uncooperative subjects
  • Parkinson's Disease
  • Vascular insufficiency of the affected limb, which could compromise bony ingrowth/implant fixation, i.e., diabetes.
  • Severe instability or deformity of the ligaments and/or surrounding soft tissue which may preclude stability of the device
  • Pregnancy
  • BMI > 40
  • Use of immunosuppressive drugs
  • Women of child bearing potential

Treatment and study plan

Bioguard Group

Device

Patients randomised to receive the study investigative device will receive a Bioguard implant

Other names: Bioguard device

Control group

Device

Patients randomised to receive the control device will receive a Exceed Taperlock implant

Other names: Exceed Taperlock

Primary outcomes

  1. Change in normalised peri-implant BMD as measured by DXA

    Time frame: 6 months post operative

Sponsors and collaborators

Lead sponsor

Zimmer Biomet

Industry

Registry information

Official study title

Prospective Clinical Investigation to Determine the Safety of Taperloc Stems With BioGuard Coating and Exceed ABT Taperfit Acetabular Cups With BioGuard Coating When Used in Cementless Total Hip Arthroplasty

Important dates

Study start
2013
Primary completion
2015
Study completion
2025
First posted
Oct 13, 2014
Registry last updated
Aug 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.